Alveo is leading the transformation of the point-of-care health technology market with a low-cost, easy-to-use, and accessible diagnostic platform. The company's be.well testing platform gives individuals access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases, pathogens, and contaminants at the point of need, improving the impact of diagnostics. Alveo was a co-winner in XPRIZE Rapid Covid Testing with the use of their be.well platform, which provides individuals with molecular testing and cloud-based analytics for rapid infectious disease diagnosis and management. Today, the be.well system enables testing for infectious diseases at the point of need in under one hour. The system includes a be.well analyzer, cartridges, assay buffer, nasal swabs, transfer pipettes, and the be.well mobile app. Alveo’s patented method uses direct electrical sensing of nucleic acid amplification in a highly efficient, low-cost, eco-friendly design. The cloud-based product platform enables the creation of vast datasets to help track global infectious disease outbreaks. Target amplification and real-time detection are contained in single-use be.well cartridges. The cartridge has multiplexing capabilities, allowing the detection of multiple pathogens in a single test.